Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

LAB

Live52w low +13.2%

Annual Quarterly

Core line items from LAB's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Annual Quarterly

Entity: STANDARD BIOTOOLS INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-10	Q1 2026 2026-03-31	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30
Revenue	$21.01M	$21.15M	$85.33M	$61.54M	$41.98M
Operating Income	Not available	$-12.50M	$-110.25M	$-85.61M	$-52.67M
Net Income	Not available	$127.07M	$-74.90M	$-94.18M	$-33.46M
EPS (Diluted)	$-0.04	$0.33	$-0.20	$-0.25	$-0.16
Total Assets	Not available	$639.11M	$567.75M	$539.64M	$556.97M
Total Liabilities	Not available	$77.99M	$143.46M	$139.98M	$132.43M
Cash & Equivalents	Not available	$265.77M	$120.86M	$129.42M	$158.62M
Free Cash Flow OCF − CapEx	Not available	$-47.17M	$-82.65M	$-80.98M	$-57.89M
Shares Outstanding	Not available	390.14M	386.38M	383.61M	381.69M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.

Core line items from LAB's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w low +13.2%

Entity: STANDARD BIOTOOLS INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-10	Q1 2026 2026-03-31	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30
Revenue	$21.01M	$21.15M	$85.33M	$61.54M	$41.98M
Operating Income	Not available	$-12.50M	$-110.25M	$-85.61M	$-52.67M
Net Income	Not available	$127.07M	$-74.90M	$-94.18M	$-33.46M
EPS (Diluted)	$-0.04	$0.33	$-0.20	$-0.25	$-0.16
Total Assets	Not available	$639.11M	$567.75M	$539.64M	$556.97M
Total Liabilities	Not available	$77.99M	$143.46M	$139.98M	$132.43M
Cash & Equivalents	Not available	$265.77M	$120.86M	$129.42M	$158.62M
Free Cash Flow OCF − CapEx	Not available	$-47.17M	$-82.65M	$-80.98M	$-57.89M
Shares Outstanding	Not available	390.14M	386.38M	383.61M	381.69M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.